InfuSystem Holdings, Inc. (NYSE:INFU - Get Free Report) Director Kenneth D. Eichenbaum bought 4,000 shares of the stock in a transaction on Monday, September 23rd. The shares were bought at an average price of $5.89 per share, with a total value of $23,560.00. Following the acquisition, the director now owns 4,000 shares of the company's stock, valued at $23,560. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
InfuSystem Stock Down 5.1 %
INFU stock opened at $5.93 on Thursday. InfuSystem Holdings, Inc. has a one year low of $5.74 and a one year high of $10.99. The company has a market cap of $126.43 million, a PE ratio of -593,000.00 and a beta of 1.46. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.64 and a current ratio of 2.07.
InfuSystem (NYSE:INFU - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.01). InfuSystem had a net margin of 0.28% and a return on equity of 0.70%. The business had revenue of $33.70 million during the quarter.
Institutional Inflows and Outflows
Watch this before it gets removed
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in InfuSystem in the 2nd quarter valued at $230,000. Marshall Wace LLP acquired a new stake in shares of InfuSystem in the 2nd quarter worth approximately $131,000. First Eagle Investment Management LLC increased its position in shares of InfuSystem by 10.0% in the second quarter. First Eagle Investment Management LLC now owns 666,048 shares of the company's stock valued at $4,549,000 after buying an additional 60,813 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of InfuSystem by 52.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company's stock valued at $178,000 after purchasing an additional 8,917 shares in the last quarter. Finally, Perritt Capital Management Inc lifted its stake in InfuSystem by 169.4% in the 2nd quarter. Perritt Capital Management Inc now owns 38,500 shares of the company's stock valued at $263,000 after buying an additional 24,207 shares in the last quarter. 71.13% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the stock. B. Riley assumed coverage on shares of InfuSystem in a research report on Thursday. They set a "buy" rating and a $13.00 target price on the stock. StockNews.com raised shares of InfuSystem from a "buy" rating to a "strong-buy" rating in a report on Friday, September 20th.
Read Our Latest Stock Report on INFU
InfuSystem Company Profile
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
